Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free Zantac cancer cases. Here at Leading Justice, we can custom tailor your firm’s Zantac advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Zantac cancer advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is evaluated to determine whether it qualifies for another type of claim. By using innovative approaches to target contacts specifically related to Zantac and side effects like bladder cancer and stomach cancer, Leading Justice will increase your firm’s Zantac cancer caseload. If you are interested in helping victims of Zantac cancer side effects, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. And while our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will customize our Zantac cancer intake specifications to the exact criteria you are seeking. So, if your firm has specific Zantac qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Zantac cancer data with zero chance of fraud.
Zantac Cancer Litigation
Zantac is one of the most popular antacid medications on the market, used by millions of people to prevent and treat heartburn, acid reflux, acid indigestion and other issues caused by too much acid in the stomach. The active ingredient in Zantac is ranitidine, which has been linked to a cancer-causing impurity known as N-nitrosodimethylamine, or NDMA. NDMA belongs to a family of chemicals known as N-nitrosamines and has been classified as a probable human carcinogen, which means it has the potential to cause cancer in humans. Among the devastating and potentially life-threatening side effects that have been linked to NDMA exposure in people taking ranitidine (Zantac) are bladder cancer, stomach cancer, gastric cancer, colon cancer, intestinal cancer, pancreatic cancer and kidney cancer.
The NDMA impurity in ranitidine-based products was first detected by Valisure, an online pharmacy that routinely tests the drugs it sells. It was in June 2019 that Valisure first reported its findings to the FDA, indicating that the NDMA found in ranitidine pills occurred at levels between 3,000 and 30,000 times what the FDA considers safe. The FDA did not take action at that time and so three months later, the pharmacy petitioned the FDA to recall ranitidine (Zantac) products in the United States. Instead, the FDA merely issued a statement notifying consumers and the medical community that “low levels” of the cancer-causing chemical NDMA had been found in samples of ranitidine, but the agency stopped short of issuing a Zantac recall. The FDA has likened the NDMA in ranitidine pills to a contamination, but there is a growing body of evidence suggesting that the ranitidine ingredient itself is the problem. Indeed, recent research has shown that ranitidine may metabolize into NDMA when ingested and that people taking ranitidine have a 400-fold increase of NDMA concentration in their urine, which means anyone taking Zantac or another ranitidine-based drug may be at risk for cancer.